Get started
Author

Mara Mantiero

Observed names: M Mantiero, M. Mantiero
ORCID: 0000-0002-1016-4995
Observed ORCID: 0000-0002-1016-4995
OpenAlex ID: A5084867713
Immunotherapy for platinum-resistant ovarian cancer
2020 · Giorgio Bogani, Salvatore Lopez, et al. · Gynecologic Oncology · 83
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease
2019 · Maria Vittoria Dieci, Vassilena Tsvetkova, et al. · Frontiers in Oncology · 71
PDF
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity
2024 · Anna Passarelli, Vittoria Carbone, et al. · Gynecologic Oncology · 46
PDF
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis
2019 · Grazia Vernaci, Maria Vittoria Dieci, et al. · The Breast · 27
PDF
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study
2019 · Tommaso Giarratano, Simona Frezzini, et al. · The Breast Journal · 26
PDF
Clinical presentation, diagnosis and management of therapy‐related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly‐ADP‐ribose polymerase inhibitors: A single‐center experience
2020 · Elisabetta Todisco, Federica Gigli, et al. · International Journal of Cancer · 16
PDF
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
2019 · Markus Joerger, Anastasios Stathis, et al. · Investigational New Drugs · 13
PDF
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study
2024 · Valentina Tuninetti, Elisa Virano, et al. · European Journal of Cancer · 9
Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer
2025 · Elena Conca, Daniele Lorenzini, et al. · Frontiers in Oncology · 8
PDF
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review
2018 · Mara Mantiero, Giovanni Faggioni, et al. · Case Reports in Oncological Medicine · 8
PDF
The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer
2023 · Monika Ducceschi, Maggie Polignano, et al. · Journal of Clinical Medicine · 7
PDF
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
2022 · Jacopo Azzollini, Andrea Vingiani, et al. · Frontiers in Oncology · 6
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)
2026 · Nicoletta Colombo, Gabriella Parma, et al. · European Journal of Cancer · 2
Peripheral Thyroid Hormones, Inflammatory and Skeletal Muscle Indexes in Advanced Cervical Cancer Treated With Cemiplimab
2025 · Valentina Tuninetti, Elisa Virano, et al. · Journal of Cachexia Sarcopenia and Muscle · 2
PDF
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?
2024 · Jacopo Azzollini, Iolanda Capone, et al. · Tumori Journal · 2
A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety
2023 · Mara Mantiero, Marta Bini, et al. · Cancers · 2
PDF
Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center
2021 · Antonino Ditto, Umberto Leone Roberti Maggiore, et al. · European Journal of Surgical Oncology · 2
1164 Alpelisib for PIK3CA-mutated advanced gynecological cancers: first clues of clinical activity
2024 · Anna Passarelli, Maria Vittoria Carbone, et al. · International Journal of Gynecological Cancer · 1
#269 Real-life experience of pazopanib in uterine leyomiosarcoma (U-LMS) in a tertiary oncologic center in Italy: evaluation of safety and effectiveness
2023 · Mara Mantiero, Monika Ducceschi, et al. · International Journal of Gynecological Cancer · 1
PDF
Empowering gynecologic oncologists: navigating new drugs and emerging toxicities
2023 · Mara Mantiero, Marta Bini, et al. · International Journal of Gynecological Cancer · 1
Comprehensive Genomic Profiling to Improve Access to Targeted Therapies in High-Grade Serous Carcinoma: A Real-World Study (PROMETHEUS)
2026 · Daniele Lorenzini, Francesca Barbetta, et al. · Journal of Molecular Diagnostics
Case Report: Personalized therapy in gynecological neuroendocrine neoplasm: a case of BRCA2-mutated ovarian neuroendocrine carcinoma treated with PARP-inhibitor
2026 · Mara Mantiero, Maggie Polignano, et al. · Frontiers in Oncology
PDF
Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management
2025 · Elena Colombo, Monika Ducceschi, et al. · Therapeutic Advances in Medical Oncology
85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial
2025 · N. Colombo, G. Parma, et al. · ESMO Open
PDF
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer: a Single Center, Open Label, Single Arm, Phase Ib/ii Trial (nichol Trial Nct06594679)
2025 · Monika Ducceschi, Salvatore Lopez, et al. · International Journal of Gynecological Cancer
Works count: 36
Citation count: 333
H-index: 8
I10-index: 7
Year
Topic
Type